Table 1 Demographic details of included studies
From: Systematic review of health related-quality of life in adults with osteogenesis imperfecta
No | Author | Country | Study design | Study size | OI type | OI diagnosis | Sex | Age (years) |
|---|---|---|---|---|---|---|---|---|
1 | Orlando [35] | UK | Cross-sectional study | n = 78 | Type 1– 32 | Self-reported | F = 74% | 43 ± 14.5a |
|  |  |  |  |  | Type 3– 10 |  | M = 26% |  |
|  |  |  |  |  | Type 4– 10 |  |  |  |
|  |  |  |  |  | Unknown– 26 |  |  |  |
2 | Murali [36] | USA | Cross-sectional study | n = 320 | Type 1– 173 | Mixed clinical/ genetic | F = 67% | 33.7 (25–47)c |
|  |  |  |  |  | Type 3– 49 |  | M = 33% |  |
|  |  |  |  |  | Type 4– 80 |  |  |  |
|  |  |  |  |  | Type 5– 5 |  |  |  |
|  |  |  |  |  | Unknown– 13 |  |  |  |
3 | Gjorup [24] | Denmark | Cross-sectional study | OI: n = 73 | T 1– 56 | Genetic | F = 55% | OI: 45.9b |
|  |  |  |  |  | T 3/4– 17 |  | M = 45% |  |
4 | Yonko [37] | Multi-national | Cross-sectional study | n = 157 | Type 1– 57 | Self-reported | F = 69% | 45.9 (19–81)d |
|  |  |  |  |  | Type 3– 39 |  | M = 30%, |  |
|  |  |  |  |  | Type 4– 33 |  | Trans man = 1% |  |
| Â | Â | Â | Â | Â | Unknown/Â other- 28Â | Â | Â | Â |
5 | Matsushita [29] | Japan | Cross-sectional study | n = 40 | Congenita– 13 | Clinical | F = 55% | 37.5e |
|  |  |  |  |  | Tarda – 25 |  | M = 45% |  |
|  |  |  |  |  | Unknown– 2 |  |  |  |
6 | Harsevoort [39] | Netherlands | Cross-sectional study | n = 99 | Type 1– 72 | N.R | F = 62% | 45 (19–80)d |
|  |  |  |  |  | Type 3– 13 |  | M = 38% |  |
|  |  |  |  |  | Type 4– 14 |  |  |  |
7 | Khan [34] | USA | Cross-sectional study | n = 30 | Type 1– 9 | Genetic 53% | F = 80% | 39 (19–67)d |
|  |  |  |  |  | Type 3– 8 | Clinical  47% | M = 20% |  |
|  |  |  |  |  | Type 4– 12 |  |  |  |
|  |  |  |  |  | Bruck Syndrome– 1 |  |  |  |
8 | Gooijer [32] | Netherlands | Cross-sectional study | n = 322 | Type 1– 220 | Genetic | F = 59% | 35.5 (27)c |
|  |  |  |  |  | Type 3– 40 |  | M = 41% |  |
|  |  |  |  |  | Type 4– 62 |  |  |  |
9 | Tosi [39] | USA | Cross-sectional study | n = 198 | Adults not reported separately | Self-reported | F = 77% | Adults' age not reported separately |
|  |  |  |  |  |  |  | M = 23% |  |
10 | Feehan [26] | Australia | Cross-sectional study | n = 52 | Less severe– 19 | N.R | F = 54% | 27.5 (23–36)c |
|  |  |  |  |  | More severe– 33 |  | M = 46% |  |
11 | Arponen [25] | Finland | Cross-sectional study | n = 56 | Type 1– 22 | Self-reported | F = 73% | 47 (16–75)d |
|  |  |  |  |  | Type 3– 10 |  | M = 27% |  |
|  |  |  |  |  | Type 4– 7 |  |  |  |
|  |  |  |  |  | Unknown– 17 |  |  |  |
12 | Hald [31] | Denmark | Cross-sectional study | n = 84 | Type 1– 58 | Genetic | F = 55% | 45 (18–78)d |
|  |  |  |  |  | Type 3– 11 |  | M = 45% |  |
|  |  |  |  |  | Type 4– 15 |  |  |  |
13 | Forestier-Zhang [23] | UK | Cross-sectional study | n = 43 | Type 1- 18 | N.R | F = 77% | 40.4 ± 14.4a |
|  |  |  |  |  | Type 3– 5 |  | M = 23% |  |
|  |  |  |  |  | Type 4– 5 |  |  |  |
|  |  |  |  |  | Unknown– 15 |  |  |  |
14 | Balkefors [33] | Sweden | Cross-sectional study | n = 29 | Type 1 + 4– 29 | N.R | F = 62% | 41 (21–71)d |
|  |  |  |  |  |  |  | M = 38% |  |
15 | Nicolaou [30] | UK | Cross-sectional study | n = 22 | Type 1– 7 | N.R | F = 59% | 24.7 (18–36)d |
|  |  |  |  |  | Type 3– 10 |  | M = 41% |  |
|  |  |  |  |  | Type 4– 5 |  |  |  |
16 | Widmann [28] | USA | Cross-sectional study | n = 30 | Congenita– 18 | Clinical | F = 70% | 33 (20–50)d |
|  |  |  |  |  | Tarda– 12 |  | M = 30% |  |
17 | Widmann [27] | USA | Cross-sectional study | n = 15 | Congenita– 7 | Clinical | F = 40% | 33.3 (20–45)d |
|  |  |  |  |  | Tarda– 8 |  | M = 60% |  |